

SIGA

# Company Overview

A Leader in Global Health  
& Infectious Diseases

March 2025



# Forward Looking Statements

The statements made in this presentation may include forward-looking statements regarding the treatment of smallpox and other orthopoxvirus infections, the development and attributes of SIGA Technologies, Inc. (“SIGA”) products, and the future operations, opportunities or financial performance of SIGA. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimations based upon the information available to SIGA as of the date of this presentation. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements.

Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.


For a more detailed discussion of our risks, see the Risk Factors section in SIGA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC and our other filings with the SEC, including our most recent Quarterly Report, all of which are available on our website, [www.siga.com](http://www.siga.com).



# Contents

- 1 **Introduction**
- 2 **The Smallpox Threat**
- 3 **TPOXX<sup>®</sup>: A Differentiated Product**
- 4 **Financial Summary**

# SIGA at a Glance




**Stellar Revenue Generation**  
>\$1bn of Procurement Contracts  
from 10+ years Working with  
Governments



**30+ Countries**  
Where Products  
Have Been Sold



**TPOXX**  
A Foundational Franchise &  
Trusted Treatment for  
Smallpox<sup>(1)</sup>



**Strong Expertise**  
Infectious Disease, Health  
Security, and Government  
Contracting

*We are dedicated to advancing our strategic initiatives, driving shareholder value, and enhancing national health security as we deliver TPOXX to U.S. and global government agencies and progress our clinical programs.*



**- Diem Nguyen, Chief Executive Officer**

## Who We Are

SIGA is a public, commercial-stage pharmaceutical company and leader in biodefense and global health security, focused on manufacturing and developing **innovative medicines** to treat and prevent **infectious diseases**, with a primary focus on **orthopoxviruses**. The company is headquartered in New York City, with research and development operations in Corvallis, Oregon.

## Development Pipeline

- Targeting regulatory submissions for new TPOXX indications, including smallpox **post-exposure prophylaxis (PEP) and a pediatric formulation**
- Moving into complementary therapeutic areas

## Strategic Priorities

1. Continue our **partnership** with the **U.S. government**
2. Advance regulatory approvals of TPOXX in new **indications and formulations**
3. Cultivate strategic partnerships to expand **global access** to TPOXX
4. Leverage capabilities to move into **complementary therapeutic areas**

<sup>1</sup> Tecovirimat-SIGA is approved by the EMA and MHRA, and TEPOXX is approved by the PMDA, for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus; TPOXX is approved by the U.S. FDA and Health Canada for the treatment of smallpox. TPOXX is not approved as a treatment for mpox in the U.S.

# SIGA is a Leader in Global Health Security



## Fully Integrated Infectious Disease Capabilities

- **Highly profitable, commercial stage** pharmaceutical company operating within infectious disease and health security
- Experienced senior management team with **deep expertise**
- Fully integrated, **U.S.-based operational supply chain**



## Leading TPOXX Product Platform

- Oral **TPOXX** is approved in the U.S., Canada, Europe, UK, and Japan
- **One of two approved antivirals** for **orthopoxvirus treatment**; strong efficacy and safety profile
- **Track record of securing multi-year government awards** with multiple governments



## Foundation for Continued Attractive Growth

- **Opportunities for TPOXX indication expansions** (post-exposure prophylaxis "PEP", pediatric formulation)
- **Geographic expansion**
- **Inorganic growth opportunities** to expand into adjacencies and complementary therapeutic areas



## Best-in-Class Financial Performance

- Realized **~\$650 mm of TPOXX revenue** with **robust gross margins** in 2020 - 2024
- Highly profitable company with **~\$370 mm in pre-tax operating income** in 2020 - 2024
- Robust balance sheet and cash flow with **minimal CAPEX** and **no debt**

# Executing on our Strategy for Growth



# Comprehensive Capabilities Provide Strong Foundation



Long-standing relationships with key government agencies  
More than a decade of contract performance



Proven R&D capabilities  
Close coordination with government agencies to jointly develop high-impact therapies  
Ongoing label expansions for TPOXX



Fully integrated U.S. end-to-end supply chain network

# Experienced Leadership in Infectious Diseases and Government Relations



**Diem Nguyen, PhD, MBA**  
Chief Executive Officer



**Dan Luckshire**  
Chief Financial Officer



**Dennis Hruby**  
Chief Scientific Officer




**Larry Miller**  
General Counsel






# Strong, Durable Financial Performance Over Time


## Product Revenues (\$mm)




## Pre-tax Operating Income (\$mm)



## Capital Management<sup>(1)</sup> (\$mm)



## Averages for 2020 – 2024 (\$mm)



## SIGA is Well Positioned Financially

- Achieved **record** 2024 product revenues through a diverse mix of customers
- Had \$70mm of **outstanding orders** at the end of 2024
- Maintains a **strong balance sheet** through disciplined cash management and no debt


((1) Includes dividends and share repurchases.



# The Smallpox Threat

# Smallpox: Historic Milestones

Highly contagious and fatal disease in susceptible population




# Smallpox Remains a Significant Threat Today

Current geopolitical environment heightens the need for vigilance

## The Growing Threat

Smallpox continues to pose a serious global threat.



More than  
**300M**  
Estimated deaths in the 20<sup>th</sup> century alone from smallpox



Smallpox can spread globally before symptoms appear, leading to catastrophic impact.



The ongoing geopolitical issues and advancements in synthetic biology are increasing the likelihood of potential threats.

## Vaccines alone may not be enough




Global travelers increase the potential exposure facilitating the rapid spread across borders



Most of today's population is no longer vaccinated against smallpox, leaving millions vulnerable to its spread.

CDC Model of a 33% transmission reduction

Result: No Control



Quarantines and vaccines alone may not be enough to stop the spread of smallpox within one year.

## Comprehensive Containment Measures are Critical



Vaccines and antivirals are both needed in a comprehensive biodefense preparedness plan, safeguarding vulnerable populations against smallpox threats.




## TPOXX: A Differentiated Product

# TPOXX at a Glance

A highly targeted antiviral treatment against orthopoxviruses, including smallpox

As the first FDA-approved antiviral treatment for smallpox, TPOXX was among the first therapies delivered to the U.S. SNS under Project BioShield. TPOXX's was developed in partnership with BARDA, and TPOXX was funded by BARDA.



TPOXX (tecovirimat) inhibits the viral envelope formation and spread of the virus  
 CEV, cell-associated virus; EEV extracellular enveloped virus; ER, endoplasmic reticulum;  
 IEV, intracellular enveloped virus; IMV, intracellular mature virus; IV, immature viruses; TGN, trans-Golgi network

## How it works

- Prevents the variola virus, which causes smallpox, from leaving infected cells
- This slows the spread of the infection and limiting it so the immune system can clear the virus
- Has a strong safety profile and is well-tolerated in patients

## Strong Preclinical and Clinical Data

- Preclinical Data** - Significantly reduced both **mortality** and **viral load** in 4 pivotal studies in non-human primates and 2 pivotal studies in rabbits.
- Clinical Data** - Studied in **17 clinical trials** involving administration in **1,300+ healthy human volunteers**. Studies provided quantifiable pharmacokinetic (PK) data within efficacious dose ranges and resulted in no serious adverse events.



## Approvals

2018	U.S. FDA
2021	Health Canada
2022	EMA

2022	Norwegian Medicines Agency
2022	MHRA - UK
2024	PMDA - Japan

# TPOXX is a Clinically Differentiated Medical Countermeasure

## Antivirals

### TPOXX Tecovirimat SIGA, TEPOXX (ST-246/tecovirimat)

- First FDA-approved drug with indication for treatment of smallpox
- Targets VP37 protein of orthopoxviruses, preventing envelopment and release of virions
- **Activity against all orthopoxviruses** tested in vitro and in multiple animal models
- **Well-tolerated** in human clinical trials

### TEMBEXA® (CMX001/brincidofovir)

- FDA-approved drug with indication for treatment of smallpox
- Targets E9L DNA polymerase of orthopoxviruses and inhibits DNA synthesis
- Exhibits antiviral activity against orthopoxviruses tested in vitro and two animal models, as well as against other DNA viruses
- **Black box warning due to increased mortality** with prolonged use in another disease
- Liver function abnormalities and gastrointestinal adverse have been observed

## Vaccines

### ACAM2000® (plus other replicating vaccinia vaccine)

- Live vaccinia virus smallpox vaccine
- May cause **serious adverse reactions** (including death), especially in immunocompromised and those with eczema or atopic dermatitis
- Up to 25% of the population would have limitations receiving the vaccine
- Most effective if given <4 days post-exposure

### IMVANEX/IMVAMUNE/ JYNNEOS® (MVA-BN®)



- Modified vaccinia virus Ankara vaccine approved for prevention of smallpox and monkeypox disease in adults 18 years of age
- Does not replicate in mammalian cells
- Well-tolerated but requires **two doses administered 28 days apart** for full efficacy




**TPOXX Demonstrates Strong Safety in Humans and Strong Efficacy in Non-Human Primates**

Note: TPOXX/Tecovirimat SIGA approved by the U.S., Canada, EU, and UK; TEMBEXA approved by the U.S. and Canada; ACAM2000 approved by the U.S., Australia, and Singapore; and MVA-BN approved by the U.S., Canada, and EU.

# Demonstrated Track-Record of >\$1B Successful Long-Standing Government Contracts for TPOXX

	2011 TPOXX CONTRACT	2018 TPOXX CONTRACT
<b>Procurement Duration</b>	2011-2018	2018-current
<b>Key Agency Involved</b>	U.S. Biomedical Advanced Research and Dev. Authority (BARDA) 	U.S. Biomedical Advanced Research and Dev. Authority (BARDA) 
<b>Contract Value</b>	<ul style="list-style-type: none"> <li>▪ \$461 mm total procurement contract value</li> <li>▪ \$461 mm fully delivered</li> </ul>	<ul style="list-style-type: none"> <li>▪ \$546 mm total procurement contract value</li> <li>▪ \$520 mm ordered; \$451 mm delivered as of 12/31/2024; \$26 mm outstanding IV procurement option</li> </ul>

 **New Contract with the Administration for Strategic Preparedness & Response (ASPR) for the U.S. National Stockpile Targeted in 2025**



# Advancing TPOXX Regulatory Approvals to Accelerate Growth into New Formulations and Indications

TPOXX Franchise is the Foundation for Expansion with over \$1bn in Multi-Year Contracts

## PEP Program

(post-exposure prophylaxis)

- Addresses **time gap** between exposure and signs of clinical infection
- Studies are supportive of the use of TPOXX in PEP to **reduce morbidity and mortality**
- Targeting FDA **submission** in 2026

## Pediatric Program

- Important program to protect the **pediatric population**
- Completed trial that demonstrates **equivalence of drug exposure** in volunteers (oral vs liquid formulation)
- Designing **clinical program** to support regulatory filing
- Selected a **manufacturer** to prepare clinical supplies


## Monoclonal Antibodies (mAbs) Program

- Obtained **license** to a portfolio of preclinical mAbs which could be used as potential treatment for orthopoxviruses

## Mpox Program

- Exploring a path forward for mpox; program is under evaluation as we analyze the data from the PALM007 and STOMP clinical trial results which read out in 2024

# TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox



PEP program has received \$27 mm of development funding from U.S. Department of Defense

# Cultivate Partnerships to Expand Global Access

Collaborating with Governments and Other Partners on Health Security is Best-in-Class Core Competency

## Strong Long-Standing Partnerships

- Public Health Emergency Medical Countermeasures Enterprise (PHEMCE)
- Biomedical Advanced Research and Development Authority (BARDA)
- Stockpiling Lifesaving Medical Countermeasures
- U.S. Department of Defense



## Proven Track Record

- Secured over \$1 bn in multi-year contracts for TPOXX
- Sold +\$130 mm of TPOXX to 30 international customers since 2020

## Common Goal of Global Health Security

- Shared understanding that with the current geopolitical environment, the risk of a rogue actor or nation weaponizing a virus has increased
- Clear recognition of the need to stockpile TPOXX and other critical medicines in the event of an outbreak to contain the impact quickly



# Financial Summary

# Strong Financial Performance

## 1 U.S. Government Orders under Current Contracts

- ~\$520 mm of TPOXX ordered for SNS over the past 5 years
- ~\$21 mm of oral TPOXX ordered by the Department of Defense over last two years

## 2 International Orders

- \$130 mm of international oral TPOXX ordered by 30 international customers since 2020

## 3 Financial Results

- Cumulative pre-tax operating income of ~\$370 mm for the 2020 – 2024 period
- 2024 product sales of \$133 mm and pre-tax operating income of \$70 mm

(\$ in millions)	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
<b>Product Sales</b>					
Oral TPOXX (U.S. Government)	\$113	\$113	\$7	\$110	\$84
Oral TPOXX (International)	\$2	\$13	\$71	\$21	\$23
IV TPOXX	-	-	\$7	-	\$26
<b>Total Product Sales</b>	<b>\$115</b>	<b>\$127</b>	<b>\$87</b>	<b>\$131</b>	<b>\$133</b>
<b>Pre-Tax Operating Income</b>	<b>\$85</b>	<b>\$89</b>	<b>\$43</b>	<b>\$84</b>	<b>\$70</b>
<b>Net Income</b>	<b>\$56</b>	<b>\$69</b>	<b>\$34</b>	<b>\$68</b>	<b>\$59</b>

# Key Takeaways

## Leveraging Infectious Disease Foundation

Leading **health security** and **infectious disease** pharmaceutical company with a **fully integrated** business with commercial, R&D, manufacturing and supply, and government relations capabilities

## Expanding Successful TPOXX Franchise

Proven **track record** of success having received > \$1 bn in **government contracts** and delivered to governments around the globe

## Driving Organic Growth Initiatives

Multiple organic **growth opportunities** across both label expansion and geographic expansion

## Expanding Platform with Inorganic Growth

Attractive opportunities to expand into **adjacencies and therapeutic areas** with scientific and commercial synergies

## Delivering Robust Financial Performance

Strong **financial growth** over time, generating significant **cash flow** for the company and shareholders



We are Well Positioned for Long-Term Growth and Attractive Future Returns